Published in Kidney Int on March 12, 2008
Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care (2009) 1.33
Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol (2010) 1.33
New pharmacological treatments for improving renal outcomes in diabetes. Nat Rev Nephrol (2010) 1.29
Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. Adv Chronic Kidney Dis (2011) 1.18
Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care (2010) 1.14
Diabetic nephropathy - complications and treatment. Int J Nephrol Renovasc Dis (2014) 1.01
Renin-angiotensin system in the kidney: What is new? World J Nephrol (2014) 0.92
Renoprotective effect of combined inhibition of angiotensin-converting enzyme and histone deacetylase. J Am Soc Nephrol (2013) 0.87
Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination. Vasc Health Risk Manag (2010) 0.87
Therapeutic approaches to slowing the progression of diabetic nephropathy - is less best? Drugs Context (2013) 0.86
Direct Renin inhibitor: aliskiren in chronic kidney disease. Nephrourol Mon (2012) 0.84
Direct renin inhibition--a promising strategy for renal protection? Med Sci Monit (2013) 0.84
Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. Clin J Am Soc Nephrol (2011) 0.84
Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy. PLoS One (2013) 0.84
Application of direct renin inhibition to chronic kidney disease. Cardiovasc Drugs Ther (2010) 0.84
Combined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats. J Cardiovasc Pharmacol (2012) 0.81
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. Vasc Health Risk Manag (2009) 0.81
The role of direct renin inhibitors in the treatment of the hypertensive diabetic patient. Ther Adv Endocrinol Metab (2013) 0.77
Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial. Int Urol Nephrol (2012) 0.77
The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy--a randomized cross-over study. PLoS One (2013) 0.77
Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease. Heart Vessels (2012) 0.76
New class of agents for treatment of hypertension: focus on direct renin inhibition. Vasc Health Risk Manag (2010) 0.76
Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences. J Clin Med (2015) 0.75
Aliskiren suppresses the renin-angiotensin-aldosterone system and reduces blood pressure and albuminuria in elderly chronic kidney disease patients with hypertension. Int J Nephrol Renovasc Dis (2012) 0.75
Direct renin inhibition in chronic kidney disease. Br J Clin Pharmacol (2013) 0.75
Aliskiren reduces home blood pressure and albuminuria in patients with hypertensive nephrosclerosis. Clin Exp Nephrol (2012) 0.75
Effects of RAAS Inhibitors in Patients with Kidney Disease. Curr Hypertens Rep (2017) 0.75
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet (2010) 11.55
Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA (2008) 7.84
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. Diabetes Care (2000) 2.97
Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation (2000) 2.90
Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia (2010) 2.35
The Evaluation of Screening and Early Detection Strategies for Type 2 Diabetes and Impaired Glucose Tolerance (DETECT-2) update of the Finnish diabetes risk score for prediction of incident type 2 diabetes. Diabetologia (2010) 2.33
Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med (2003) 2.28
Diabetes, prediabetes and cancer mortality. Diabetologia (2010) 2.22
Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes--the EURODIAB Prospective Complications Study. Diabetologia (2005) 2.16
Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med (1999) 2.03
Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist. Br Med J (Clin Res Ed) (1982) 2.02
Semi-automatic assessment of skin capillary density: proof of principle and validation. Microvasc Res (2013) 2.01
[Chronic renal disease as cardiovascular risk factor]. Ned Tijdschr Geneeskd (2008) 1.94
Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol (2001) 1.92
Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J (2000) 1.75
ANTI-HSP60 and ANTI-HSP70 antibody levels and micro/ macrovascular complications in type 1 diabetes: the EURODIAB Study. J Intern Med (2009) 1.68
Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia (2005) 1.58
Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy. Diabetologia (1995) 1.57
In-training assessment: qualitative study of effects on supervision and feedback in an undergraduate clinical rotation. Med Educ (2006) 1.56
Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia (2004) 1.56
Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Kidney Int (2001) 1.55
Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes. Diabetologia (2012) 1.55
Autonomic nervous function, arterial stiffness and blood pressure in patients with Type I diabetes mellitus and normal urinary albumin excretion. J Hum Hypertens (2004) 1.51
Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis (2008) 1.50
[(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab (2001) 1.50
Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients. Diabetologia (1991) 1.47
Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study. Diabetologia (2005) 1.46
Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int (2000) 1.46
Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials. Diabetologia (2011) 1.46
Progression of diabetic nephropathy. Kidney Int (2001) 1.46
Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial. Diabetologia (2008) 1.44
Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women. Clin Sci (Lond) (2003) 1.43
Both resistance- and endurance-type exercise reduce the prevalence of hyperglycaemia in individuals with impaired glucose tolerance and in insulin-treated and non-insulin-treated type 2 diabetic patients. Diabetologia (2011) 1.42
Five-year incidence of type 2 diabetes mellitus in patients with familial combined hyperlipidaemia. Neth J Med (2010) 1.42
A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells. Immunol Today (1997) 1.42
Comparison of the efficacies of disinfectants to control microbial contamination in dental unit water systems in general dental practices across the European Union. Appl Environ Microbiol (2006) 1.42
Differential release of amino acids, neuropeptides, and catecholamines from isolated nerve terminals. Neuron (1991) 1.41
'Pseudo-aldosteronism' induced by intravenous glycyrrhizin treatment of chronic hepatitis C patients. J Gastroenterol Hepatol (2001) 1.41
Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med (2005) 1.40
Cardiac peptides differ in their response to exercise. Implications for patients with heart failure in clinical practice. Eur Heart J (1999) 1.40
Support for adrenaline-hypertension hypothesis: 18 hour pressor effect after 6 hours adrenaline infusion. Lancet (1988) 1.40
[Diagnostic and prognostic value of B-type natriuretic peptides in heart failure or signs of heart failure]. Ned Tijdschr Geneeskd (2007) 1.40
Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients. Diabetes Care (1998) 1.40
Growth hormone treatment improves body fluid distribution in patients undergoing elective abdominal surgery. Clin Endocrinol (Oxf) (1998) 1.39
Brain natriuretic peptide in hemodynamically stable acute pulmonary embolism. J Thromb Haemost (2005) 1.38
Discontinuation of metformin in type 2 diabetes patients treated with insulin. Neth J Med (2002) 1.38
Effectiveness of clinical rotations as a learning environment for achieving competences. Med Teach (2004) 1.35
Opposite effects of captopril on angiotensin I-converting enzyme 'activity' and 'concentration'; relation between enzyme inhibition and long-term blood pressure response. Clin Sci (Lond) (1981) 1.31
Brisk walking compared with an individualised medical fitness programme for patients with type 2 diabetes: a randomised controlled trial. Diabetologia (2008) 1.29
Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy. Diabetologia (2004) 1.29
Individuals at increased coronary heart disease risk are characterized by an impaired microvascular function in skin. Eur J Clin Invest (2003) 1.28
Cytokine-stimulated secretion of group II phospholipase A2 by rat mesangial cells. Its contribution to arachidonic acid release and prostaglandin synthesis by cultured rat glomerular cells. J Clin Invest (1993) 1.28
Congenital dopamine-beta-hydroxylase deficiency. A novel orthostatic syndrome. Lancet (1987) 1.25
Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int (2006) 1.24
Short stature and diabetic nephropathy. BMJ (1995) 1.24
Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. Eur J Clin Invest (2009) 1.22
The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med (2004) 1.21
Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes (1995) 1.20
Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol (2006) 1.20
Obesity-associated low-grade inflammation in type 2 diabetes mellitus: causes and consequences. Neth J Med (2013) 1.20
Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. Diabet Med (2010) 1.17
Effects of captopril in acute and chronic heart failure. Correlations with plasma levels of noradrenaline, renin, and aldosterone. Br Heart J (1983) 1.15
In vivo effects of sex steroids on lymphocyte responsiveness and immunoglobulin levels in humans. J Clin Endocrinol Metab (2000) 1.14
Body fat loss achieved by stimulation of thermogenesis by a combination of bioactive food ingredients: a placebo-controlled, double-blind 8-week intervention in obese subjects. Int J Obes (Lond) (2006) 1.14
Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia (2004) 1.14
Alanine aminotransferase and the 6-year risk of the metabolic syndrome in Caucasian men and women: the Hoorn Study. Diabet Med (2007) 1.14
The central roles of obesity-associated dyslipidaemia, endothelial activation and cytokines in the Metabolic Syndrome--an analysis by structural equation modelling. Int J Obes Relat Metab Disord (2002) 1.13
Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia (2006) 1.12
Therapy with interleukin-2 induces the systemic release of phospholipase-A2. Cancer Immunol Immunother (1995) 1.12
[Guideline 'Cardiovascular Risk Management']. Ned Tijdschr Geneeskd (2007) 1.11
Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation (2003) 1.11
Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. Kidney Int (1996) 1.09
Coffee consumption and incidence of impaired fasting glucose, impaired glucose tolerance, and type 2 diabetes: the Hoorn Study. Diabetologia (2004) 1.09
[Estimate of the number of new patients with type 2 diabetes mellitus in the Netherlands: at least 65,000 per year in the age group of 50 years and above]. Ned Tijdschr Geneeskd (2003) 1.08
Fatigue in primary Sjögren's syndrome. Ann Rheum Dis (1998) 1.08
Sympathetic and parasympathetic components of reflex cardiostimulation during vasodilator treatment of hypertension. Br J Clin Pharmacol (1980) 1.08
QTc interval length and QT dispersion as predictors of mortality in patients with non-insulin-dependent diabetes. Scand J Clin Lab Invest (2000) 1.08
Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney Int Suppl (2000) 1.07